The Modern Cat May Have Emerged From Ancient Egyptian Ritual Sacrifice
The macabre world of ancient Egyptian ritual sacrifice may have contributed to the domestication of cats, new research suggests.
Mummified cats (Felis catus) were such a common offering to the Egyptian gods around 3,000 years ago that humans started breeding them (along with other sacrificial species).
It's estimated ancient Egyptians mummified up to 70 million animals including cats, shrews, falcons, crocodiles, and ibis during their reign in North Africa.
Raising cats together in large numbers to meet this demand would have favored more social and docile individuals. These tamer kitties were likely then traded across continents.
Another theory suggests cats gradually domesticated themselves in Europe during the Neolithic period, as humans transitioned into farming, providing felines with an ample supply of rodents that fed off our crops. This may have inspired rat-plagued farmers to encourage their presence for vermin control.
The discovery of a 9,500-year-old grave in 2004, containing human and cat remains in Cyprus, seemed to support the Neolithic domestication theory. But domestic cat morphology and DNA do not corroborate this scenario, two new studies, both still awaiting peer review, have now found.
University of Exeter zooarchaeoligst Sean Doherty and colleagues compared the bones of domestic cats with European wildcats (Felis silvestris) and found their features are no more similar than domestic cats are to African wildcats (Felis lybica).
What's more, the Cyprus grave kitty is morphologically more similar to the European wildcat, not African. Its genetic material is, unfortunately, too degraded for study.
A non-European origin of F. catus is also corroborated by research from paleogeneticist Marco De Martino from the University of Rome Tor Vergata. His team's genetic analysis supports African wildcats as the ancestors of domestic cats.
Examining 70 ancient cat genomes from archaeological sites across Europe, Anatolia, North Africa, Bulgaria, and Italy, the analysis appears to pinpoint the domestic cat's most likely place of origin.
"Our results demonstrate that the dispersal of present-day domestic cats can be traced back not to the Neolithic or from the Fertile Crescent, but instead several millennia later and most likely from North Africa," write De Martino and colleagues.
These genes revealed two waves of spread into the Mediterranean, the first during the 1st millennium BCE that introduced a wild population on the island of Sardinia, and a later wave that became the domestic cats we still coddle today.
The team found F. catus didn't reach China until about the 8th century CE.
Other researchers still argue the cat domestication process began centuries before Egypt's mass sacrifices. Instances of human relationships with cats certainly occurred multiple times, including the example in Cyprus as well as early Egyptian burials with cats around 3800 BCE, but these are not necessarily from the same line of cats that became F. catus.
The earliest genetically confirmed domestic cat is a mummified sacrifice as early as 500 BCE.
"Genome data from modern and ancient cats from Egypt, which are currently lacking, will allow these two hypotheses to be tested," De Martino and team concede.
If Egyptian origins of F. catus hold true, it wouldn't be the first time religious worship spurred humans to carry animals with them, both teams of researchers point out.
"Cults and religions are often drivers for animal translocations. For instance, the spread of fallow deer has been directly linked to the cults of Artemis and Diana, while chickens were associated with Mercury and Mithras," write Doherty and team.
"The Egyptian goddess Bastet … first appeared in the 3rd millennium BCE depicted with a lion's head, but during the 9th-7th centuries BCE she was increasingly represented with the head of an African wildcat. This transformation was coincident with the rise of cat sacrifice, whereby millions of free-ranging and specifically-reared cats were mummified as offerings to the goddess."
With such brutal acts at the start of our relationship with felines, it seems fitting cats have kept their temperamental reputations.
This research is awaiting peer review, and can be found here and here on bioRxiv.
Giant Prehistoric Kangaroos in Australia Were Doomed, And Now We Know Why
Wild Chimps Caught on Camera Sharing Alcoholic Fruit
Earth's Rotation Is Slowing Down, And It Could Explain Why We Have Oxygen
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
High Growth Tech Stocks in Europe to Watch for Potential Expansion
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt further monetary easing by the European Central Bank. In this context of potential expansion and shifting economic policies, high-growth tech stocks become particularly intriguing for investors seeking opportunities that align with evolving market dynamics and technological advancements. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 228 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €226.34 million. Operations: Oryzon Genomics specializes in discovering and developing epigenetics-based therapeutics targeting cancer and CNS disorders. Oryzon Genomics, a trailblazer in epigenetic therapies, is making significant strides with an impressive 49.3% annual revenue growth forecast. Despite its current unprofitability, the company's strategic focus on R&D (13.26 million EUR allocated to the VANDAM project) underscores its commitment to addressing rare neurodevelopmental disorders and neuroendocrine tumors through precision medicine. The recent 15 million EUR grant for this project enhances Oryzon's potential in pioneering treatments that could revolutionize patient care in these underserved areas. Additionally, their involvement in high-profile clinical trials like the Phase I/II trial of iadademstat for small cell lung cancer further exemplifies their innovative approach within the biotech sector. With expected profitability and earnings growth of 50.17% per annum over the next three years, Oryzon is positioned to leverage its scientific advancements into commercial success. Click to explore a detailed breakdown of our findings in Oryzon Genomics' health report. Explore historical data to track Oryzon Genomics' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Atea ASA is a leading provider of IT infrastructure and related solutions for businesses and public sector organizations across the Nordic countries and Baltic regions, with a market capitalization of NOK16.73 billion. Operations: Atea ASA generates revenue primarily from its operations in Norway, Sweden, Denmark, Finland, and the Baltics. The highest revenue contribution comes from Sweden at NOK13.06 billion, followed by Norway at NOK9 billion. Group Shared Services account for NOK10.81 billion in costs. Atea's strategic emphasis on R&D, with a notable 13% of its revenue directed towards innovation, underpins its robust position in the European tech landscape. Despite a challenging year with earnings growth contracting by 8.8%, the company's revenue is still expected to outpace the Norwegian market, growing at 9.4% annually compared to the market's 2.6%. This resilience is further highlighted by Atea's recent dividend affirmation, committing NOK 786 million back to shareholders, showcasing confidence in its financial health and ongoing value creation strategies. Dive into the specifics of Atea here with our thorough health report. Examine Atea's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Paradox Interactive AB (publ) is a company that focuses on developing and publishing strategy and management games for PC and consoles across various global regions, with a market cap of approximately SEK20.90 billion. Operations: The company generates revenue primarily from its Computer Graphics segment, amounting to SEK2.18 billion. It operates in diverse regions including North and Latin America, Europe, the Middle East, Africa, and the Asia Pacific. Paradox Interactive, amidst a dynamic European tech landscape, continues to innovate and expand its gaming universe. The company's recent announcement of two new DLC packs for "Across the Obelisk" underscores its commitment to enhancing player experience and broadening content availability across multiple platforms. Strategic alliances like the one seen with Room 8 Group for "Crusader Kings III: Legacy of Persia" not only diversify Paradox's portfolio but also deepen its historical game narratives, reinforcing its niche in strategy games. Financially, Paradox is poised for growth with a revenue increase of 9.3% annually and an earnings forecast growing at 21.5% per year, complemented by a robust R&D investment strategy that ensures continuous innovation and competitiveness in the high-stakes gaming market. Click here and access our complete health analysis report to understand the dynamics of Paradox Interactive. Gain insights into Paradox Interactive's historical performance by reviewing our past performance report. Take a closer look at our European High Growth Tech and AI Stocks list of 228 companies by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OB:ATEA and OM:PDX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Avicenna.AI Secures CE Mark for Two Spine-Focused Medical Imaging AI Tools
EU certification granted for AI algorithms for vertebral compression fracture quantification and cervical spine fracture detection. MARSEILLE, France, June 5, 2025 /PRNewswire/ -- Medical imaging AI company today announced that it has received CE Mark certification for CINA-VCF Quantix, a new AI algorithm designed to detect and assess unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions. The company also secured CE Mark certification for CINA-CSpine, an AI tool designed to detect and triage cervical spine fractures from CT images. The CE mark signifies that both products meet the stringent health and safety standards required by the European Union, enabling them to be deployed across the European Economic Area without additional regulatory barriers. VCFs, often caused by bone deterioration due to osteoporosis, can lead to significant pain, deformity, and height loss. In the U.S. alone, approximately 750,000 adults suffer osteoporotic VCFs annually, but nearly two-thirds go undiagnosed, increasing the risk of further fractures and complications. CINA-VCF Quantix is intended for patients aged 50 and older undergoing CT scans of the chest and/or abdomen for other conditions. The tool automatically labels vertebrae and calculates vertebral height loss ratios in the thoracic and lumbar spine. If a vertebral height loss ratio exceeds 20%–25%, indicating a moderate to severe VCF, CINA-VCF Quantix generates a passive notification, prompting radiologists to report early findings and supporting proactive patient care. "Osteoporotic vertebral fractures can have a profound impact on patients' quality of life. The launch of CINA-VCF Quantix in Europe represents a major step forward in preventive care, empowering clinicians to intervene before minor fractures escalate," said Cyril Di Grandi, co-founder and CEO of "By encouraging the reporting of VCF presence and severity, CINA-VCF Quantix has the potential to make a real difference in long-term patient outcomes." Cervical spine fractures, typically caused by trauma, involve breaks in one or more of the seven cervical vertebrae in the neck. If the spinal cord is affected, these fractures can cause neurological damage or paralysis. Early diagnosis and treatment are critical to improving outcomes and minimizing long-term complications. CINA-CSpine automatically flags suspected acute cervical spine fractures, alerting radiologists through their existing systems for faster diagnosis and intervention. "The launch of CINA-CSpine in the European market marks a significant step forward in trauma care. By reducing the time between scan and diagnosis, we're helping radiologists catch cervical spine fractures faster and more reliably — a crucial advance when every minute counts," said Di Grandi. "CINA-CSpine serves as a second pair of eyes, enhancing diagnostic confidence and ultimately improving patient outcomes across Europe." All of products are seamlessly integrated into radiologists' clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists. The company's product portfolio also includes AI tools for: Intracranial hemorrhage (CINA-ICH) Large vessel occlusion (CINA-LVO) Aortic dissection (CINA-AD) Pulmonary embolism (CINA-PE and CINA-iPE) Vertical compression fractures (CINA-VCF) And ASPECT Score for quantification of stroke severity (CINA-ASPECTS). About in 2018, specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify severe pathologies from CT medical images. Co-founded by Cyril Di Grandi, a successful entrepreneur who previously co-founded Olea Medical, and Dr. Peter Chang, an internationally recognized radiologist, and an expert in AI and deep learning, aims to accelerate therapeutic decision-making processes and enhance patient outcomes through its AI-based radiology solutions. For additional details, stay connected with us on social media and explore website at View original content: SOURCE
Yahoo
3 hours ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@